“A leading endocrinologist with the Food and Drug Administration recommended pursuing approval for puberty blockers for youth with gender dysphoria despite acknowledging that they raised the risk of depression and suicidality, according to internal emails. Shannon Sullivan, the clinical team leader at the FDA’s Division of General Endocrinology, recommended to her supervisor in January 2022 that the agency approve puberty blockers to treat adolescents with gender dysphoria following a safety review that showed negative mental health results.”
“Sullivan’s emails were obtained through a lawsuit discovery process from the nonprofit advocacy group America First Legal and published by the Daily Signal.”
Read the full story on the Washington Examiner here.
Follow us on social media for the latest updates on America First Legal’s fight to protect your constitutional rights!
X, Facebook, GETTR, Instagram, Truth Social
For press inquiries, please contact [email protected].
